Skip to main navigation Skip to content

Search whole site

Back to all Current clinical trials
RC-48

The trial is testing a potential new treatment called disitamab vedotin  for Muscle-invasive Bladder Cancer.

  • Category
  • Trial status
    Active, not recruiting
  • Trial phase
    Phase 2 Drug Trial
    Early stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
  • Registry listing
  • ERM Project ID
    89018

Trial contact details

What you need to know

Who can take part?

Patients with locally confined or Metastatic muscle invasive bladder cancer.

What is involved for you?

All patients in this trial will receive the investigational product via an IV infusion every two weeks.  As part of each clinic visit, blood will be taken, a physical exam will be conducted and an ECG will be performed.

Back to all Current clinical trials